Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol PK in Renal Impairment
NCT03882762Phase 1Completed
- Sponsor
- Tris Pharma
- Start
- Jun 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cebranopadol in pain (4 arms), sponsored by Tris Pharma. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 7 more. Started Jun 2013; status: completed.
02
Drugs
cebranopadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT03882762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882762.